J INTS BIO to Present Global Clinical Results from JIN-A02, a Fourth-Generation EGFR-TKI, at ASCO 2025
Significant anti-tumor responses and reduction of brain metastases observed
SEOUL, South Korea , June 1, 2025 /PRNewswire/ -- J INTS BIO, a company specializing in the development of therapeutics for cancer and rare diseases, officially announced interim results from the global Phase 1/2 clinical trial of JIN-A02, its fourth-generation EGFR-TKI drug candidate, at the American Society of Clinical Oncology 2025 (ASCO 2025), the world's largest oncology conference, held in Chicago, USA.
JIN-A02 is an oral, fourth-generation EGFR-TKI designed to overcome resistance mutations (such as C797S) that develop after treatment failure with third-generation EGFR-TKIs, which are currently the first-line therapy for EGFR-mutant Non-small cell lung cancer (NSCLC). It is currently undergoing clinical trials in South Korea, the United States, Thailand, and other countries. Key efficacy and safety results from Part A (dose escalation) of the multi-center clinical trial (NCT05394831) were presented.
'Confirmed' clinical response observed in patients with disease progression after 3rd Generation EGFR TKI and chemotherapy
One of the key findings of the ASCO presentation was that tumor responses were sustained in specific dose cohorts, with confirmed partial responses (PRs) verified by independent evaluation. Confirmed PRs were observed in 50mg,100mg and 300mg QD dose groups, providing clinical evidence of anti-tumor activity.
In the 50 mg dose group, patients achieved a 77.3% reduction in tumor size, maintaining a PR over six consecutive treatment cycles (from cycle 3 to cycle 13). In the 300 mg dose group, a confirmed PR was observed with a 39.7% tumor size reduction, including a significant reduction in brain metastatic lesions. In the 100 mg dose group, a PR was also reported with a 35.3% reduction in tumor size, and brain metastatic lesions remained stable, further supporting the potential of JIN-A02 in treating brain metastases.
Safety confirmed up to 300 mg, with therapeutic signals in brain metastases
No dose-limiting toxicities (DLTs) or serious adverse events were observed with JIN-A02 at doses up to 300mg, which is six times the dose level when PR was first observed, demonstrating a favorable safety profile even at higher dose levels. The majority of adverse events reported at 300mg were mild (Grade 1-2) and included for the first time, Grade 1 skin rash, diarrhea, and skin desquamation in 3 out of 5 subjects – events commonly associated with EGFR inhibitors and generally considered clinically manageable. Importantly, there were no reports of systemic toxicities such as cardiovascular events or hepatotoxicity, supporting the drug's excellent safety profile. This safety and tolerability have translated into extended treatment durations in real-world settings, with a patient still on JIN-A02 after one year and seven months.
In addition, the trial demonstrated notable responses in brain metastases first noted at 100mg, suggesting that JIN-A02 achieves therapeutically relevant concentrations in brain tissue.
JIN-A02 gains national spotlight as government grants accelerate development
In addition to the ASCO announcement, J INTS BIO continues to achieve noteworthy results in Korea. Recently, it was selected for the '2025 Baby Unicorn Fostering Project' by the Ministry of SMEs and Startups, officially recognizing both our scientific technology and commercialization potential. The 'Baby Unicorn Fostering Project' is a government project that focuses on developing promising startups with innovative technologies and growth potential in the global market as 'potential unicorns'. Companies selected for this project will receive full government support in recognition of their technological prowess and growth potential.
With these accolades, JIN-A02 will receive dual funding for its Phase 2 trial and global expansion over the next two years, which is expected to be a decisive point to significantly accelerate the pace of clinical and commercialization in parallel with private investment. It is also significant as a case of securing confidence in the 3 arena of technology, marketability, and global scalability, as the recognition came from different government departments.
Based on these achievements, we plan to initiate the Phase 2 clinical trial of JIN-A02 in before the end of this year, in discussions with the US FDA.
'The ASCO presentation of JIN-A02's ability to induce anti-cancer responses and its ability to respond to central nervous system metastatic lesions is of great significance,' said Dr. Anna Jo, CEO. 'The government's continued support is a recognition of our technical capabilities and potential for growth. We will take advantage of this opportunity to accelerate global clinical expansion, technology transfer, and indication expansion to realize our goal of early commercialization'
View original content to download multimedia: https://www.prnewswire.com/news-releases/j-ints-bio-to-present-global-clinical-results-from-jin-a02-a-fourth-generation-egfr-tki-at-asco-2025-302470257.html
SOURCE J INTS BIO
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNN
13 minutes ago
- CNN
‘It is a whole different environment': Republicans revisit key Biden investigations with new momentum
The House Judiciary Committee is expected to interview former Hunter Biden special counsel David Weiss behind closed doors on Friday, two sources familiar with the interview told CNN, as part of a broader Republican effort to revisit previous probes into the Biden family that stalled last Congress but are gaining new momentum now that Republicans control both chambers of Congress and the White House. The scheduled interview, which could still be moved, would be the second time the Republican-led panel will interview Weiss about his work as Republicans continue to probe whether the investigation was hampered by political interference. Weiss has still never testified publicly about his six-year criminal probe into the president's son, which included three convictions, but was ultimately short-circuited as a result of the former president's unconditional pardon of his son. House Judiciary Republicans have long wanted to call Weiss, the Trump-appointed US attorney, back for questioning after his first closed-door interview in 2023. Committee Republicans were also able to finally secure interviews with two Department of Justice tax division prosecutors involved in the Hunter Biden probe who they had been aggressively pursuing for months, one of the sources familiar told CNN. The Justice Department is working with Weiss to provide access to documents he may need for his interview, a person briefed on the matter said. Any delays in getting access to documents would be a scheduling issue and the ability to have personnel who can oversee it, the person briefed on the matter said. It's not the only Biden investigation Republicans are reexamining that leans into a fresh political appetite with GOP control of Washington. House Oversight Chair James Comer is returning to his probe of the former president's mental fitness in an entirely new landscape after a recent book by CNN's Jake Tapper and Axios' Alex Thompson put Joe Biden's physical and mental decline back in the spotlight. Comer told CNN he is in the process of scheduling key interviews with Biden's White House physician, Dr. Kevin O'Connor, and other senior aides who had all rebuffed his efforts last Congress. Beyond the five initial interviews from Biden's orbit, the Republican Chairman told CNN he wants to look at the executive orders Biden signed in his last six months in office and use of the autopen. In the weeks immediately after Biden's disastrous 2024 debate performance that unraveled his presidential campaign and upended the Democratic party, Comer requested to interview Biden's doctor and subpoenaed three senior Biden aides to discuss their roles in the Biden White House, which never materialized. Now, Comer said in an interview with CNN, 'it is a whole different environment.' At the time of his 2024 interview requests, Comer's impeachment inquiry into the Biden family's business dealings had fallen apart and the Biden administration felt no incentive to comply with the House Oversight Committee. Probing Biden's decline now, Comer says, will be a lot easier than trying to convince his colleagues of an alleged Biden family foreign influence peddling scheme, which even Comer conceded was difficult to do, particularly in a minute or less on Fox News. Republicans failed to uncover evidence to support their core allegations against the president, and lacked the votes in their divided, narrow majority last Congress to impeach the president. 'The money laundering and the shell companies, the average American couldn't understand that. I mean, that was hard to understand,' Comer told CNN. 'You know, I did not do a good job explaining that.' But with his investigation into Biden's mental and physical decline, Comer said, 'people see a president that clearly is in decline. They saw it in the debate.' Democrats sought to dismantle the Republican-led 11 month impeachment inquiry into Biden last Congress at every turn. Comer told CNN that although those Democrats aren't jumping at the opportunity to cooperate now, he does not see them as being obstructive either. 'I take that as a step in the right direction,' he told CNN. Tapper and Thompson's book documents how Biden, his closest aides and his family forged ahead with the former president's doomed 2024 reelection bid despite signs of his physical and mental decline. In a previous statement to CNN, a Biden spokesman criticized the book, saying that evidence shows that 'he was a very effective president.' Former Democratic Rep. Dean Phillips, who launched a long-shot challenge to Biden and was outspoken about his concerns over the former president's age, told CNN he did not think there needed to be an investigation on Capitol Hill at this point into Biden's fitness as president. 'This case already went to trial, the jury of American voters convicted the party of the accused, and handed out the harshest political punishment possible-losing the single most consequential election in modern history,' Phillips told CNN. Instead, Phillips called on Biden to authorize his physician to disclose his health file and condition under oath. 'Only if the former president refuses, or if questioning uncovers possible criminal activity, should an investigation be initiated,' Phillips added. Biden was recently diagnosed with an 'aggressive form' of prostate cancer.
Washington Post
15 minutes ago
- Washington Post
McCarthy, Vikings value Jefferson's presence and leadership in offseason practices
EAGAN, Minn. — The Minnesota Vikings urged Justin Jefferson to fully participate in their offseason program, a commitment some established NFL stars aren't willing to make each spring. The sixth-year wide receiver was already a step ahead of the coaching staff. This is a critical offseason for Jefferson and the Vikings, breaking in a new quarterback in J.J. McCarthy , so he was planning to make his attendance a priority. 'It's definitely important to gain a little bit of a sight of what the new year is coming to look like, to build that connection with my teammates and especially with my quarterback,' Jefferson said after practice on Monday. 'It's definitely great to be out here early to kind of get into the feel.' These late spring practices, known in league parlance as organized team activities, are when the basic installation of the playbook begins, even though only the three-day minicamp next week is contractually mandated. It's also a prime opportunity to build that rhythm and trust between the quarterback and his receivers. 'He's a tremendous talent, tremendous leader, but his leadership really shows up when he's here,' said McCarthy, who accompanied Jefferson to a Timberwolves playoff game last month when they sat together in courtside seats. 'Just being able to get that chemistry building on and off the field has been invaluable.' Jefferson, whose 7,432 receiving yards are the most in league history through a player's first five seasons, said he doesn't concern himself with the style or tendencies of who's throwing. 'As long as the ball gets close to my face, I'm going to try to catch it,' he said. 'It doesn't matter how fast the ball is going, the spin of it or if it's coming from a lefty or a righty. My job is to catch the ball.' What's most important to Jefferson is the quarterback learning to adjust to his route-running preferences, with an exceptional stride length and side-to-side agility that helps set him apart. 'It's that timing, those reps,' McCarthy said. 'All of that has to be built up over time.' Which is why Jefferson being around all the time is so valuable. 'He's an energy igniter of the whole building, and I think he's come back with a purpose and a mindset,' coach Kevin O'Connell said. 'You hear his voice, you hear his interaction with teammates, and they just carry such a long way.' Not just for the quarterback. 'The guys in that locker room know, 'If this guy, one of the best in the world at what he does, is pushing himself in May and June, I sure as heck better be doing the same thing,'' O'Connell said. McCarthy, whose rookie season was spent entirely in the training room recovering from knee surgery, at least had some meaningful time in strategy meetings that helped him start to build the knowledge base in the offense even if he wasn't taking snaps on the field. 'I've been really surprised by some of the things that he does know. You're like, 'Man, we covered that in a 10-minute burst in Week 11 last year. How do you remember that?'' O'Connell said. 'And then there's some other things where you're like, 'Oh, I assumed he knew that.' So it's our job — baseline teaching and stacking days and layered learning so that we're constantly making him feel like he's growing but never comfortable.' Jefferson can see that too. 'He definitely has an arm, that's for sure. He can definitely zip it whenever he needs to,' he said, before recounting his advice to McCarthy at this stage of the offseason. 'Just let everything happen. Don't try to make the best play every single play.' ___ AP NFL:
Bloomberg
18 minutes ago
- Bloomberg
Trump Revokes Biden-Era Rule on Emergency Abortions in Hospitals
The Trump administration rescinded guidance put in place by former President Joe Biden that directed US hospitals to provide abortions on an emergency basis when they're medically necessary to stabilize patients. The guideline was established in July 2022 under the Emergency Medical Treatment and Labor Act, just weeks after the US Supreme Court overturned the Roe v. Wade decision that protected national abortion rights. It was enacted under the Centers for Medicare and Medicaid Services after women reported being turned away from hospitals while facing serious pregnancy complications, including severe bleeding.
